The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. Objective: The objective of this article is to gain insight into the re-innovation model in some of the innovative generic pharmaceutical firms. To this effect, we show how some of the generic pharmaceutical firms attempt to achieve competitive advantages either by improving existing product attributes or by replacing new components, reshaping their configuration, and using new technology platforms to produce new innovative products. Methods: We used a qualitative method to examine re-innovation at several levels within these companies, in their management systems, business models and product portfolios. The research was conducted by a series of semi-structured interviews with chief executive officers, consultants, researchers, patent attorneys, pharmacists and medics in different countries. Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. Conclusion: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.
Authors and Affiliations
Fereshteh Barei, Claude Le Pen, Steven Simoens
Keywords
Related Articles
- EP ID EP355082
- DOI 10.5639/gabij.2013.0201.011
- Views 139
- Downloads 0
Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective
Aim: To provide a systematic overview on: i) safety profiles; ii) pharmacokinetic parameters; and iii) regulatory framework of anti-cancer tyrosine kinase inhibitors (TKI). Methodology: Recherché of pharmakokinetic (PK)-...
Biosimilars naming and prescribing policy in Australia
To the Editor: I wanted to bring to your attention the following paper which was published in Volume 2/Year 2013/Issue 3 of the Generics and Biosimilars Initiative Journal. The Perspective paper titled Licensing and pr...
Biosimilarity of anticancer monoclonal antibodies in the clinic
The European Medicines Agency recommends the use of pharmacodynamics (PD) markers when establishing biosimilarity, but no such biomarkers are known for the clinical efficacy of bevacizumab (Avastin). For this reason, con...
Latest features in GaBI Journal, 2012, issue 3-4
This issue of the GaBI Journal uses a number of article formats to cover a range of issues related to generics and biosimilars.
The future of biological therapy: a pathway forward for biosimilars
Biologicals are advanced prescription drugs to treat cancer, rheumatoid arthritis HIV/AIDS, multiple sclerosis and other debilitating diseases. In November 2010, the US Food and Drug Administration (FDA) began consultati...